A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome

This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)

NCT Number	NCT07695298
Lead Sponsor	Cincinnati Eye Institute, Southwest Ohio Collaborators: Genentech, Inc.
Conditions	Presumed Ocular Histoplasmosis
Enrollment	25 participants
Start Date	2026-07
Primary Completion	2028-05 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-10